A recent clinical investigation has shown the JAK1/JAK3 inhibitor tofacitinib to be a promising salvage therapy for refractory T-LGL leukemia patients with or without STAT3 mutations [35]. The gene discussed is JAK1; the disease is T-cell large granular lymphocyte leukemia.